Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Harvard Bioscience, Inc. Schedules Second Quarter 2013 Conference Call for August 1, 2013



Harvard Bioscience, Inc. Schedules Second Quarter 2013 Conference Call for
August 1, 2013

HOLLISTON, Mass., July 31, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc.
(Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range
of specialized products used to advance life science research and regenerative
medicine, will announce results for its second quarter ended June 30, 2013
before market trading hours on Thursday, August 1, 2013.

A conference call to discuss the company's second quarter ended June 30, 2013
financial results is scheduled for Thursday, August 1, 2013 at 11:00 a.m.
Boston time. In addition, management may answer questions concerning business
and financial developments and trends, the Company's view on earnings
forecasts, update on its regenerative medicine device business, and other
business and financial matters affecting the Company. Some of the information
to be presented on the call or provided in response to questions may contain
information that has not previously been disclosed.

The conference call will be simultaneously broadcast over the Internet and can
be accessed through the Harvard Bioscience, Inc. website. To listen to the
conference call, log on to our website at www.harvardbioscience.com and click
on the Earnings Call icon. Financial and other statistical information
presented on the call, including our earnings release, will also be available
on the investor relations section of our website. Click on the investor
relations button and then click on the press release or webcast icon, as
appropriate. If you are unable to listen to the live webcast, the call will be
archived in the investor relations section of our website. The live conference
call is also accessible by dialing toll-free 877-303-7611, or toll
970-315-0445, and referencing the pass code of "21825448".

Date: August 1, 2013
Time: 11:00 AM ET

Listen via Internet: http://www.harvardbioscience.com/

A replay of this conference call will be available from approximately 2:00
p.m. on August 1, 2013 through August 10, 2013 and will be accessible by
dialing toll-free 855-859-2056, or toll 404-537-3406, and referencing the pass
code of "21825448".

Harvard Bioscience ("HBIO") is a global developer, manufacturer and marketer
of a broad range of specialized products, primarily apparatus and scientific
instruments, used to advance life science research and regenerative medicine.
HBIO sells its products to thousands of researchers in over 100 countries
primarily through its 850 page catalog (and various other specialty catalogs),
its website, through distributors, including GE Healthcare, Thermo Fisher
Scientific and VWR, and via its field sales organization. HBIO has sales and
manufacturing operations in the United States, the United Kingdom, Germany,
Sweden and Spain with additional facilities in France and Canada. For more
information, please visit www.harvardbioscience.com.

The Harvard Bioscience, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6426

The statements made in this press release that are not statements of
historical fact are forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These statements involve known and unknown risks, uncertainties
and other factors that may cause the Company's actual results, performance or
achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking statements.
Factors that may cause the Company's actual results, performance or
achievements to differ materially from those in the forward-looking statements
include, but are not limited to, those factors set forth under the heading
"Item 1A. Risk Factors" in the Company's Quarterly Report on Form 10-Q for
the quarter ended March 31, 2013 or described in the Company's other public
filings. The Company's results may also be affected by factors of which the
Company is not currently aware. The Company may not update these
forward-looking statements, even though its situation may change in the
future, unless it has obligations under the federal securities laws to update
and disclose material developments related to previously disclosed
information.

CONTACT: Harvard Bioscience, Inc.
        
         David Green, President and Interim CEO
         dgreen@harvardbioscience.com
        
         Tom McNaughton, CFO
         tmcnaughton@harvardbioscience.com
        
         Tel: 508 893-8999
         Fax: 508 892-6135

Harvard Bioscience, Inc. Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement